Form 4: Prelude Therapeutics Inc. Executive Awarded Stock Options

Peggy Scherle, Chief Scientific Officer of Prelude Therapeutics Inc., was granted stock options for 150,000 shares on March 1, 2024.

Summary

• Peggy Scherle, the Chief Scientific Officer of Prelude Therapeutics Inc., received stock options to purchase 150,000 shares of common stock on March 1, 2024.
• The exercise price of the options is $4.59 per share.
• The options vest as to 25% on March 1, 2025, and then 1/48 monthly until fully vested, contingent upon continued service to the company.
• The options expire on February 28, 2034.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice and indicates confidence in the executive and the company's future performance. There are no explicitly negative aspects mentioned.

Positives

• The grant of stock options to the Chief Scientific Officer aligns her interests with those of the shareholders.
• The vesting schedule incentivizes continued service and contribution to the company's success.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align their interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in publicly traded biotechnology companies.
• The size of the grant and the vesting schedule are typical for executives at this level.
• Comparable companies such as Arcus Biosciences, Mirati Therapeutics, and Relay Therapeutics also utilize stock options as part of their executive compensation packages.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the Chief Scientific Officer to drive company performance.
• Employees may see this as a positive sign of investment in leadership.

Key Dates